As an E2F target, Dnmt1 (DNA methytrasferase 1) showed differential expression throughout tumor progression (expression fold changes in PyMT tumors vs. FVB controls during hyperplasia, adenoma/MIN, early carcinoma, and late carcinoma are 2.0, 2,5, 2.3, and 3.2 (FDR < 0.05), respectively). Here, DNMT1 is linked to carcinoma.